Signaling-biased mu opioid receptor agonists
10751335 ยท 2020-08-25
Assignee
Inventors
- Thomas D. Bannister (Palm Beach Gardens, FL)
- Laura M. Bohn (Jupiter, FL, US)
- Cullen L. Schmid (Cambridge, MA, US)
Cpc classification
A61K31/4166
HUMAN NECESSITIES
C07D401/04
CHEMISTRY; METALLURGY
International classification
A61K31/454
HUMAN NECESSITIES
C07D401/04
CHEMISTRY; METALLURGY
Abstract
The invention providesopioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.
Claims
1. A compound of structure 1 ##STR00077## with substituents R.sup.1-R.sup.9, specified as follows: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are each independently H, Cl, Br, F, OCF.sub.3, Me, or lower alkyl, provided that one or more of groups R.sup.1-R.sup.4 is not a hydrogen atom; R.sup.5 is H, Cl, Br, F, Me, CF.sub.3, OCF.sub.3, OCHF.sub.2, OCH.sub.2F, OMe, O-alkyl, SMe, S-alkyl, NH-acyl, or N(Me)-acyl; R.sup.6 is H, Cl, Br, F, Me, Et, lower alkyl, CF.sub.3, OCF.sub.3, OCHF.sub.2, OCH.sub.2F, OMe, O-alkyl, SMe, S-alkyl, NH-acyl, or N(Me)-acyl wherein when R.sup.5 and R.sup.6 both are O-alkyl they may be connected together in a ring of 5-7 atoms by 1-3 CH.sub.2 groups; R.sup.7Cl, Br, F, Me, CF.sub.3, OCF.sub.3, OCHF.sub.2, or OCH.sub.2F; provided that one or more of groups R.sup.5-R.sup.7 is also not a hydrogen atom; R.sup.8H, Me, or Et; and R.sup.9H, Me, Et, lower alkyl, or CH.sub.2-cycloalkyl; or, where a chiral carbon is present, an R-enantiomer, S-enantiomer, or racemic mixture thereof; and/or a pharmaceutically acceptable salt thereof.
2. A compound selected from any of the following compounds or, where a chiral carbon is present, an R-enantiomer, S-enantiomer, or racemic mixture thereof: and/or a pharmaceutically acceptable salt thereof: ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083##
3. A pharmaceutical composition comprising a compound or, where a chiral carbon is present, an R-enantiomer, S-enantiomer, or racemic mixture thereof, and/or a or pharmaceutically acceptable salt thereof of claim 1 or 2 and a pharmaceutically acceptable excipient.
4. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein when a chiral carbon is present, the compound is a racemate.
5. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein when a chiral carbon is present, the compound is the R-enantiomer.
6. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein when a chiral carbon is present, the compound is the S-enantiomer.
Description
BRIEF DESCRIPTION OF THE FIGURES
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
DETAILED DESCRIPTION
(9) The following discloses various embodiments of the present invention, chemical compounds and compositions and therapeutic methods of use thereof.
Embodiment 1
(10) A compound of structure 1 with suitable substituents R.sup.1-R.sup.8, specified as follows.
(11) ##STR00001##
(12) 1) One or more groups R.sup.1-R.sup.4 is not a hydrogen atom.
(13) 2) One or more groups R.sup.5-R.sup.7 is also not a hydrogen atom.
(14) 3) R.sup.1, R.sup.2, R.sup.3, and R.sup.4 independently=H, Cl, Br, F, OCF.sub.3, Me, lower alkyl.
(15) 4) R.sup.5H, Cl, Br, F, Me, CF.sub.3, OCF.sub.3, OCHF.sub.2, OCH.sub.2F, OMe, O-alkyl, SMe, S-alkyl, NH-acyl, N(Me)-acyl, phenyl, aryl, heteroaryl, O-phenyl, O-aryl, O-heteroaryl; wherein the phenyl, aryl, heteroaryl, O-phenyl, O-aryl, or O-heteroaryl groups may be substituted with one or more groups among F, Cl, Me, CF.sub.3, and lower alkyl.
(16) 5) R.sup.6H, Cl, Br, F, Me, Et, lower alkyl, CF.sub.3, OCF.sub.3, OCHF.sub.2, OCH.sub.2F, OMe, O-alkyl, SMe, S-alkyl, NH-acyl, N(Me)-acyl, phenyl, aryl, heteroaryl, O-phenyl, O-aryl, O-heteroaryl; wherein the phenyl, aryl, heteroaryl, O-phenyl, O-aryl, or O-heteroaryl groups may be substituted with one or more groups among F, Cl, Me, CF.sub.3, and alkyl. In cases where R.sup.5 and R.sup.6 both are O-alkyl they may be connected together in a ring of 5-7 atoms using 1-3 CH.sub.2 groups.
(17) 6) R.sup.7Cl, Br, F, Me. CF.sub.3, OCF.sub.3, OCHF.sub.2, OCH.sub.2F.
(18) 7) R.sup.8H, Me, Et (including all stereoisomers).
(19) 8) R.sup.9H, Me, Et, lower alkyl, CH.sub.2-cycloalkyl.
(20) Also encompassed are all pharmaceutically acceptable salt forms, hydrates, solvates, and polymorphic crystalline forms thereof, as well as amorphous forms thereof. All stereoisomeric and isotopic forms are also encompassed.
Embodiment 2
(21) A compound of embodiment 1 that shows mathematically defined functional selectivity, displaying bias for G protein signaling over arrestin2 recruitment or receptor phosphorylation profiles, wherein functional selectivity with respect to arrestin2 recruitment bias is defined as having a G/arr bias factor >1.0, with the G protein signaling efficiency is assessed using a standard [.sup.35S]GTPS binding assay, as described herein.
Embodiment 3
(22) A compound of embodiment 1 that shows significant and unexpected bias for G protein signaling, having a G/arr bias factor >3.0, with the G protein signaling efficiency is assessed using a standard [.sup.35S]GTPS binding assay, as described herein.
Embodiment 4
(23) A compound of embodiment 1 that shows significant and unexpected bias for G protein signaling, having a G/arr bias factor >9.0, with the G protein signaling efficiency is assessed using a standard [.sup.35S]GTPS binding assay, as described herein.
Embodiment 5
(24) A compound of any one of embodiments 2-4 that shows significant effects upon pain perception in humans and/or other mammals.
Embodiment 6
(25) A compound of embodiment 5 in a suitable pharmaceutical formulation for use in humans and/or other mammals.
Embodiment 7
(26) A compound of embodiment 1, wherein the compound is any of the following compounds, including all stereoisomeric forms, all isotopic forms, all crystalline and amorphous forms, and all pharmaceutically acceptable salt forms thereof:
(27) ##STR00002## ##STR00003## ##STR00004## ##STR00005##
Embodiment 8
(28) A pharmaceutical composition comprising a compound of any one of embodiments 1-7 and a pharmaceutically acceptable excipient.
Embodiment 9
(29) A compound of any one of embodiments 1-7 for treatment of pain in a mammal.
Embodiment 10
(30) A method of treatment of pain in a mammal, comprising administering to the mammal an effective dose of the compound of any one of embodiments 1-7.
Embodiment 11
(31) The method of embodiment 10, wherein the mammal is a human.
Embodiment 12
(32) The method of embodiment 11 wherein the pain is chronic pain or acute pain.
Embodiment 13
(33) The method of embodiment 10 wherein the compound promotes antinociception, with fewer or diminished side effects, relative to a dose of morphine that promotes a comparable degree of antinociception.
Embodiment 14
(34) The method of embodiment 13, wherein the side effects that are absent or attenuated in the treated patient include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, elevated heart rate, and post-treatment withdrawal symptoms.
(35) Compounds of the invention may be prepared as described in the General Reaction Scheme 1 shown below:
(36) ##STR00006## ##STR00007##
(37) The following compounds were made according to the methods of General Scheme 1:
(38) TABLE-US-00001 TABLE 1 step 5 reaction identification example structure R groups conditions numbers 1
METHODS AND EXAMPLES (CHEMISTRY)
(39) All reagents and anhydrous solvents were used as obtained from commercial vendors. .sup.1H NMR spectra reported in Examples were recorded on a Brker Ultrashield 400 at 400 MHz. Chemical shifts are reported in parts per million (ppm) using an internal standard, CHCl.sub.3 ( 7.26), MeOH ( 3.34) or DMSO ( 2.54). Mass spectra were recorded on a Thermo/Finnegan LCQ Duo system. Analytical HPLC spectra were obtained using an Agilent 1100 reverse phase analytical HPLC instrument, with conditions and columns as indicated. HPLC method 1 was routinely used: column=Zorbax 5 m Eclipse-XDB-C18 80 LC column (1554.6 mm), column temperature=40 C., flow rate=3.00 mL/min. The method incorporates a gradient elution, beginning with 98% H.sub.2O/2% acetonitrile, each with 0.1% TFA. After 1 minute, hydrophobicity was increased to 5% acetonitrile and then linearly in a gradient to 95% acetonitrle over an additional 5 minutes. Detection was by UV absorbance at multiple wavelengths, typically 215, 254, and 280 nm.
Example 1
1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one
(40) ##STR00033##
(41) Step 1. 1,2-Dichloro-4-fluoro-5-nitrobenzene (0.43 mL, 3.3 mmol) was added to a solution of tert-butyl 4-aminopiperidine-1-carboxylate (655 mg, 3.3 mmol) and K.sub.2CO.sub.3 (497 mg, 3.6 mmol, 1.1 equiv.) in DMSO (5 mL) and the solution was stirred at room temperature under argon overnight. Reaction progress was monitored by LCMS and upon completion, water (20 mL) was added and the organic layer extracted with ethyl acetate (315 mL). The combined organic layers were then washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. Purification was achieved by flash column chromatography on silica gel using a gradient of ethyl acetate:hexanes as the eluent. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as an orange solid. 788 mg of the product tert-butyl 4-((4,5-dichloro-2-nitrophenyl)amino)piperidine-1-carboxylate was obtained (62%).
(42) Step 2. The product of step 1 (788 mg, 2.0 mmol) was dissolved in ethanol (40 mL) and a 50% aqueous suspension of Raney nickel (5 mL) was added. Hydrazine hydrate (0.98 mL, 20.0 mmol) was then added dropwise to the stirred mixture over 10 min. The mixture was heated to 45 C. and maintained at that temperature until HPLC analysis indicated that the reaction was complete (10 min). The mixture was filtered through a pad of Celite which was washed with methanol (330 mL). The solvent was removed under reduced pressure. Purification was achieved by flash column chromatography on silica gel using a gradient of ethyl acetate: hexanes as the eluent Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as an gray solid. 552 mg of the product tert-butyl 4-((2-amino-4,5-dichlorophenyl)amino)piperidine-1-carboxylate was obtained (76%).
(43) Step 3. The product of step 2 (550 mg, 1.5 mmol) was dissolved in THF (15 mL) under argon and 1,1-carbonyldiimidazole (347 mg, 2.1 mmol) was added in one portion. The solution was stirred at room temperature overnight. Reaction progress was monitored by LCMS and upon completion the solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (20 mL). This reaction mixture was washed with 1M HCl (215 mL), brine (15 mL), and dried over sodium sulfate and the solvent was removed under reduced pressure. Purification was achieved by flash column chromatography on silica gel using a gradient of ethyl acetate: hexanes as the eluent. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as a gray powder. 538 mg of the product tert-butyl 4-(5,6-dichloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate was obtained (91%).
(44) Step 4. The product of step 3 (538 mg, 1.4 mmol) was dissolved in a 33% solution of trifluoroacetic acid in dichloromethane (4 mL). Reaction progress was monitored by LCMS and after 2 hours the solvent was removed under reduced pressure and the residue was dissolved in a minimal amount of water-acetonitrile (1:1). The solution was frozen and then was subjected to lyophilization overnight, giving the product as a grey solid, in the form of a trifluoroacetic acid salt. This material was taken to step 5 without further purification, obtained in 86% crude yield.
(45) Step 5. NaBH(OAc).sub.3 (169 mg, 0.81 mmol) was added to an anhydrous dichloroethane (3 mL) solution of the product of step 4, 5,6-dichloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (102 mg, 0.27 mmol), and 4-bromo-2-fluorobenzaldehyde (162 mg, 0.81 mmol). The mixture was stirred at room temperature under argon. A few drops of acetic acid were added to the solution, which was then stirred overnight under argon. Reaction progress was monitored by LCMS and when complete, saturated sodium bicarbonate (5 mL) was added to the reaction mixture, which was then diluted with dichloromethane (10 mL). The aqueous layer was extracted with dichloromethane (210 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure. Purification was achieved by flash column chromatography on silica gel using dichloromethane:methanol as the eluent. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as a clear residue. This residue was dissolved in a minimal amount of water-acetonitrile (1:1). The solution was frozen and subjected to lyophilization overnight, giving the product as a white powder. 48.1 mg of the product 1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one was obtained (38%).
(46) Acids (e.g., HCl, MeSO.sub.3H, CF.sub.3CO.sub.2H, etc.) could be added to the product before the lyophilization step to give the corresponding addition salts of the product. As one example, the mesylate salt was obtained as follows: Methanesulfonic acid (13.1 L, 0.20 mmol) was added to a suspension of 1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one (prepared as described above, following the flash chromatography element of step 5, 95.9 mg, 0.20 mmol) in ethanol (2 mL). The mixture was heated to 60 C. for 30 min. The solvent was evaporated under reduced pressure to give the product as a clear residue. This residue was dissolved in a minimal amount of water-acetonitrile (1:1). The solution was frozen and subjected to lyophilization overnight, giving 1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one methanesulfonate as an white powder (92.3 mg, 85% yield).
(47) Supporting data for the product of Example 1: .sup.1H NMR of the mesylate salt (400 MHz, MeOD) 7.64-7.55 (m, 3H), 7.47 (s, 1H), 7.20 (s, 1H), 4.53 (tt, J=18.58, 4.23, 1H), 4.45 (s, 2H), 3.70 (d, J=12.68, 2H), 3.37-3.26 (m, 2H), 2.83-2.69 (m, 5H), 2.09 (d, J=14.88, 2H). MS(m/z): [M+H] calc'd for C.sub.19H.sub.17BrCl.sub.2FN.sub.3O 472.00 and 474.00, found 472.31 and 474.18. HPLC t.sub.R=4.00 min (HPLC method 1); purity=95.4%. .sup.1H NMR of the free base form (400 MHz, CDCl.sub.3) 8.94 (s, 1H), 7.36-7.22 (m, 4H), 7.16 (s, 1H), 4.25 (tt, J=18.79, 4.30, 1H), 3.60 (s, 2H), 3.04 (d, J=11.44, 2H), 2.38 (qd, J=12.39, 3.45, 2H), 2.22 (t. J=11.08, 2H), 1.80 (dd, J=11.82, 2.41, 2H).
Example 2
1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one
(48) ##STR00034##
(49) This compound was made according to the method of Example 1, with the alteration in step 5 of using procedure B, including titanium (IV) isopropoxide added prior to the addition of the reducing agent, which was in this case NaBH.sub.3CN. Procedure B was always used when a substituted acetophenone compound was used as the carbonyl group-containing reactant in step 5.
(50) Steps 1-4: Repeat of steps 1-4 in Example 1.
(51) Step 5. Ti(Oi-Pr).sub.4 (0.5 mL, 1.6 mmol) was added to the product of step 4, 5,6-dichloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (67.2 mg, 0.16 mmol), and 1-(4-bromophenyl)ethanone (100.0 mg, 0.5 mmol) under argon. The reaction mixture was heated to 60 C. for 2 hours. The solution was then cooled to room temperature and ethanol (2 mL) was added followed by NaCNBH.sub.3 (86.4 mg, 1.4 mmol) and mixture was stirred overnight under argon. The reaction progress was monitored by LCMS and upon completion saturated sodium bicarbonate (10 mL) was added. The quenched reaction was then filtered through a pad of Celite and washed with dichloromethane (310 mL) and methanol (210 mL). The solvents were removed under reduced pressure and then the residue was dissolved in dichloromethane. This solution was washed with water. The aqueous layer was extracted with dichloromethane (310 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, and concentrated under reduced pressure. Purification was achieved using preparative HPLC column chromatography and 0.1% TFA in H.sub.2O:methanol:acetonitrile as the eluent. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as a colorless solid, as the trifluoroacetic acid salt. This residue was dissolved in a minimal amount of water-acetonitrile (1:1). The solution was frozen and subjected to lyophilization overnight, giving the product as a white solid, in the form of a trifluoroacetic acid salt. 27.2 mg of the product 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one (trifluoroacetic acid salt) was obtained (28%).
(52) Other acid addition salts (e.g., HCl, MeSO.sub.3H, etc.) can be obtained instead of the trifluoroacetic acid salts by neutralization to the free base form followed by acid addition and isolation as shown for the mesylate salt in Example 1.
(53) Supporting data for the product of Example 2 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 9.06 (s, 1H), 7.47 (d, J=8.40, 2H), 7.31 (s, 1H), 7.24 (d, J=8.48, 2H), 7.16 (s, 1H), 4.19 (tt, J=18.93, 4.27, 1H), 3.47 (q, J=6.70, 1H), 3.19 (d, J=10.40, 1H), 2.95 (d, J=9.88, 1H), 2.44-2.22 (m, 2H), 2.13 (td, J=17.63, 2.19, 1H), 2.02 (td, J=17.78, 2.23, 1H), 1.82 (d, J=13.00, 1H), 1.72 (d, J=12.17, 1H), 1.38 (d, J=6.72, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.20BrCl.sub.2N.sub.3O, 468.0 and 470.0; found, 468.8 and 470.2. HPLC t.sub.R=4.01 min (HPLC method 1); purity=98.7%.
(54) Anticipated procedural variations for Examples 1-2: The reagents used in these Examples are fully suited for the indicated syntheses but an experimentalist is not limited to the described reagents and/or reaction conditions, as one of ordinary skill may recognize other suitable reagents and/or reaction conditions. Specific common variants are here specified: While tert-butyl 4-aminopiperidine-1-carboxylate was used as the starting material, other N.sup.1-protecting groups on the 4-aminopiperidine reactant can instead be used, with a corresponding adjustment in how step 4 (protecting group removal) is conducted. Bases and solvents other than the indicated K.sub.2CO.sub.3 in DMSO method are suitable for use in step 1. Reducing conditions other than the indicated combination of Raney nickel and hydrazine in ethanol can be used for nitro group reduction in step 2. Reagents other than carbonyl diimidazole can be used in step 3 to form the benzimidazolone ring, including triphosgene or a phosgene solution, as examples. Other reaction conditions and/or reducing agents may be used in step 5 to form the indicated products. The purification protocols, by flash chromatography or by preparative HPLC, may be used interchangeably in either example. Other purification methods may alternatively be used (e.g., recrystallization).
Example 3
1-(1-(1-(4-bromo-2-fluorophenyl)ethyl)piperidin-4-yl)-5-chloro-1H-benzo[d]imidazol-2(3H)-one
(55) ##STR00035##
(56) This compound was made according to the method of Example 2, following General Scheme 1 but beginning with the commercially available starting material 5-chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one (obtained from Acros Organics). This material corresponds to the product of step 4 in General Scheme 1. It was converted to the product using 1-(4-bromo-2-fluorophenyl)ethanone, Ti(OiPr).sub.4, NaBH(OAc).sub.3s and THF in step 5, as generally described in Example 2, with purification by flash chromatography. The yield for the final step was 56%.
(57) Supporting data for the product of Example 3 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.53 (s, 1H), 7.31-7.19 (m, 2H), 7.15 (d, J=9.36, 1H), 7.08 (d, J=8.40, 1H), 6.98-6.92 (m, 2H), 4.13-4.18 (m, 1H), 3.83 (q, J=12.96, 6.83, 1H), 3.15 (d, J=12.96, 1H), 2.89 (d, J=10.48, 1H), 2.29 (dq, J=12.32, 4.28, 1H), 2.42-2.19 (m, 1H), 2.09-1.86 (m, 2H), 1.75 (d, J=12.44, 1H), 1.65 (d, J=11.16, 1H), 1.31 (d, J=6.72, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.20BrClFN.sub.3O, 452.0 and 454.0; found, 452.6 and 454.0. HPLC t.sub.R=5.02 min (HPLC method 1); purity=99.0%.
Example 4
1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-5-chloro-1H-benzo[d]imidazol-2(3H)-one
(58) ##STR00036##
(59) This compound was made according to the method of Example 3, using 1-(4-bromo-2-fluorophenyl)ethanone in the final step. The yield was 63%.
(60) Supporting data for the product of Example 4 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 10.12 (s, 1H), 7.37-7.22 (m, 3H), 7.16 (d, J=8.16, 1H), 7.12 (d, J=1.96, 1H), 7.02 (dd, J=8.48, 2.00, 1H), 4.31 (tt, J=12.41, 4.23, 1H), 3.60 (s, 2H), 3.04 (d, J=11.40, 2H), 2.49-2.35 (m, 2H), 2.24 (t, J=11.28, 2H), 1.80 (dd, J=11.94, 2.02, 2H), MS(m/z): [M+H] calc'd for C.sub.19H.sub.18BrClFN.sub.3O, 438.03 and 440.03; found, 438.63 and 440.11. HPLC t.sub.R=3.66 min (HPLC method 1); purity=95.3%.
Example 5
5-chloro-1-(1-(1-(4-(ethylthio)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(61) ##STR00037##
(62) This compound was made according to the method of Example 3, using 1-(4-(ethylthio)phenyl)ethanone. Ti(OiPr).sub.4 and NaBH(OAc).sub.3 in the final step. The yield was 45%.
(63) Supporting data for the product of Example 5 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 10.08 (s, 1H), 7.23-7.17 (m, 4H), 7.09 (d, J=8.48, 1H), 7.03 (d, J=2.00, 1H), 6.94 (dd, J=8.48, 2.04, 1H), 4.18 (tt, J=16.69, 4.24, 1H), 3.43 (q, J=13.40, 6.64, 1H), 3.10 (d, J=11.44, 1H), 2.89-2.84 (m, 3H), 2.35 (dq, J=12.28, 4.04, 1H), 2.24 (dq, J=12.36, 3.91, 1H). 2.08 (dt, J=11.60, 2.16, 1H), 1.96 (dt, J=11.72, 2.12, 1H) 1.73 (dd, J=10.64, 2.02, 1H), 1.65-1.63 (m, 1H), 1.30 (d. J=6.93, 3H), 1.25 (t, J=8.01, 3H), MS(m/z): [M+H] calc'd for C.sub.22H.sub.26ClN.sub.3OS, 416.1; found, 416.1. HPLC t.sub.R=3.97 min (HPLC method 1); purity=99.9%.
Example 6
1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-6-chloro-1H-benzo[d]imidazol-2(3H)-one
(64) ##STR00038##
(65) This compound was made according to the method of Example 2, using 5-chloro-1-fluoro-2-nitrobenzene in step 1 and 1-(4-bromophenyl)ethanone, Ti(OiPr).sub.4 and NaBH(OAc).sub.3 in the final step. The overall yield was 20%.
(66) Supporting data for the product of Example 6 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 9.83 (s, 1H), 7.40 (d, J=7.47, 2H), 7.17-6.92 (m, 5H), 4.29-4.09 (m, 1H), 3.39 (d, J=5.52, 1H), 3.12 (d, J=9.04, 1H), 2.87 (d, J=8.52, 1H), 2.36-2.24 (m, 2H), 1.94-2.11 (m, 2H) 1.77-1.61 (m, 2H), 1.31 (d, J=5.20, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.21BrClN.sub.3O, 434.0 and 436.0; found, 434.0 and 436.0. HPLC t.sub.R=4.07 min (HPLC method 1); purity=99.0%.
Example 7
5-chloro-1-(1-(1-(4-chloro-2-fluorophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(67) ##STR00039##
(68) This compound was made according to the method of Example 3, using 1-(4-chloro-2-fluorophenyl)ethanone, Ti(Oi-Pr).sub.4 and NaBH(OAc).sub.3 in the final step, following the general protocol of Example 2. The overall yield was 31%.
(69) Supporting data for the product of Example 7 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.98 (s, 1H), 7.32 (t. J=16.09, 8.08, 1H), 7.09-6.99 (m, 4H), 6.96 (dd, J=10.44, 2.00, 1H), 4.16 (tt, J=12.48, 4.24, 1H), 3.85 (q, J=13.64, 6.76, 1H), 3.16 (d, J=11.56, 1H), 2.90 (d, J=11.24, 1H), 2.36 (dq, J=12.36, 4.12, 1H), 2.24 (dq, J=12.40, 3.92, 1H), 2.12-2.07 (m, 1H), 1.93 (dt, J=11.56, 1.80, 1H) 1.67-1.60 (m, 2H), 1.32 (d, J=6.80, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.20Cl.sub.2FN.sub.3O, 408.1; found, 408.4. HPLC t.sub.R=3.73 min (HPLC method 1); purity=99.8%.
Example 8
6-bromo-1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(70) ##STR00040##
(71) This compound was made according to the method of Example 2, using 4-bromo-2-fluoro-1-nitrobenzene in step 1 and 1-(4-bromophenyl)ethanone. Ti(Oi-Pr).sub.4 and NaBH(OAc).sub.3 in the final step. The overall yield was 5%.
(72) Supporting data for the product of Example 8 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.77 (s, 1H), 7.46 (d, J=8.36, 2H), 7.31 (d, J=1.08, 1H), 7.20-7.15 (m, 2H), 7.10 (dd, J=8.32, 1.77, 1H), 6.86 (d, J=6.32, 1H), 4.13 (tt, J=12.48, 4.08, 1H), 3.41 (q, J=13.32, 6.60, 1H), 3.13 (d, J=10.64, 1H), 2.87 (d, J=10.32, 1H), 2.29 (dq, J=12.32, 4.28, 1H), 2.24 (dq, J=12.16, 3.96, 1H), 2.10-2.05 (m, 1H), 1.98 (dt, J=11.96, 2.00, 1H) 1.75 (d, J=12.40, 1H), 1.64 (d, J=12.12, 1H), 1.31 (d, J=6.72, 3H). MS(m/z): [M+H] calc'd for C.sub.20H.sub.21Br.sub.2N.sub.3O, 480.1: found. 480.2. HPLC t.sub.R=3.93 min (HPLC method 1); purity=99.8%.
Example 9
6-chloro-1-(1-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)
(73) ##STR00041##
(74) This compound was made according to the method of Example 6, using 1-(4-(trifluoromethyl)phenyl)ethanone in step 5. The overall yield was 17%.
(75) Supporting data for the product of Example 9 includes: .sup.1H NMR (400 MHz, MeOD) 7.56 (d, J=8.20, 2H), 7.48 (d, J=8.21, 2H), 7.37 (d, J=1.64, 1H), 6.94 (dd, J=8.32, 1.80, 1H), 6.89 (d J=8.32, 1H), 4.09 (tt, J=12.52, 4.40, 1H), 3.40 (q, J=8.00, 1H), 3.22-3.20 (m, 1H), 2.91-2.86 (m, 1H), 2.35 (dq, J=12.28, 4.04, 1H), 2.42 (dq, J=12.52, 4.72, 1H), 2.10 (dt, J=11.92, 2.56, 1H), 1.99 (dt, J=12.00, 2.44, 1H) 1.72-1.56 (m, 2H), 1.37 (d, J=6.76, 3H), MS(m/z): [M+H] calc'd for C.sub.21H.sub.21ClF.sub.3N.sub.3O, 424.1; found, 424.4. HPLC t.sub.R=5.23 min (HPLC method 1); purity=96.1%.
Example 10
5-chloro-1-(1-(1-(4-(trifluoromethyl)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(76) ##STR00042##
(77) This compound was made according to the method of Example 3, using 1-(4-(trifluoromethyl) phenyl)ethanone, Ti(OiPr).sub.4 and NaBH(OAc).sub.3 in the final step. The overall yield was 21%.
(78) Supporting data for the product of Example 10 includes: .sup.1H NMR (400 MHz, MeOD) 7.56 (d, J=8.20, 2H), 7.48 (d, J=8.24, 2H), 7.22 (d, J=9.04, 1H), 6.98-6.94 (m, 2H), 4.09 (tt, J=12.44, 4.36, 1H), 3.39 (q, J=13.56, 6.80, 1H), 3.21-3.17 (m, 1H), 2.89-2.82 (m, 1H), 2.44 (dq, J=12.40, 4.12, 1H), 2.30 (dq, J=12.48, 4.04, 1H), 2.10 (dt, J=11.92, 2.56, 1H), 1.98 (dt, J=12.00, 2.36, 1H) 1.70-1.58 (m, 2H), 1.36 (d, J=6.76, 3H), MS(m/z): [M+H] calc'd for C.sub.21H.sub.21ClF.sub.3N.sub.3O, 424.1; found, 424.3. HPLC t.sub.R=5.17 min (HPLC method 1); purity=95.0%.
Example 11
1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-5-chloro-1H-benzo[d]imidazol-2(3H)-one
(79) ##STR00043##
(80) This compound was made according to the method of Example 3, using 1-(4-bromophenyl)ethanone, Ti(OiPr).sub.4 and NaBH(OAc).sub.3 in the final step. The overall yield was 19%.
(81) Supporting data for the product of Example 11 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 9.01 (s, 1H), 7.37 (d, J=8.36, 2H), 7.16 (d, J=8.36, 2H), 7.08 (d, J=18.48, 1H), 6.99 (d, J=1.92, 1H), 6.95 (dd, J=8.40, 1.92, 1H), 4.15 (tt, J=12.32, 3.92, 1H), 3.38 (q, J=13.20, 6.56, 1H), 3.10 (d, J=10.68, 1H), 2.85 (d, J=9.72, 1H), 2.32 (dq, J=12.44, 4.12, 1H), 2.23 (dq, J=12.20, 3.88, 1H), 2.09-1.94 (m, 2H) 1.74 (d, J=10.80, 1H), 1.64 (d, J=11.28, 1H), 1.28 (d, J=6.72, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.21BrClN.sub.3O, 434.1 and 436.1; found, 434.1 and 436.1. HPLC t.sub.R=3.82 min (HPLC method 1); purity=99.9%.
Example 12
1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-4-chloro-1H-benzo[d]imidazol-2(3H)-one
(82) ##STR00044##
(83) This compound was made according to the method of Example 2, using 1-chloro-3-fluoro-2-nitrobenzene in step 1 and 1-(4-bromophenyl)ethanone, Ti(OiPr).sub.4 and NaBH(OAc).sub.3 in the final step. The overall yield was 14%.
(84) Supporting data for the product of Example 12 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.63 (s, 1H), 7.49 (d, J=8.48, 2H), 7.28-7.26 (m, 3H), 7.05 (dd, J=8.32, 1.84, 1H), 6.98 (d, J=8.28, 1H), 4.25 (tt, J=12.56, 4.32, 1H), 3.48 (q, J=13.36, 6.64, 1H), 3.21 (d, J=9.96, 1H), 2.98-2.94 (m, 1H), 2.43 (dq, J=12.76, 4.24, 1H), 2.33 (dq, J=12.36, 4.08, 1H), 2.17 (dt, J=11.72, 2.40, 1H), 2.06 (dt, J=11.72, 2.24, 1H), 1.86-1.73 (m, 2H), 1.40 (d, J=6.72, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.21BrClN.sub.3O, 434.1 and 436.1; found, 434.1 and 436.1. HPLC t.sub.R=3.88 min (HPLC method 1); purity=99.9%.
Example 13
1-(1-(1-(4-bromo-2-fluorophenyl)ethyl)piperidin-4-yl)-4-chloro-1H-benzo[d]imidazol-2(3H)
(85) ##STR00045##
(86) This compound was made according to the method of Example 12, using 1-(4-bromo-2-fluorophenyl)ethanone in the final step. The overall yield was 13%.
(87) Supporting data for the product of Example 13 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 9.09 (s, 1H), 7.37-7.15 (m, 4H), 6.96 (dd, J=8.32, 1.84, 1H), 6.90 (d, J=8.32, 1H), 4.14 dt, J=12.56, 4.12, 1H), 3.85 (q, J=13.60, 6.76, 1H), 3.19 (d, J=10.76, 1H), 2.87 (dd, J=29.44, 9.32, 1H), 2.36 (dq, J=12.32, 4.08, 1H), 2.24 (dq, J=12.24, 4.24, 1H), 2.15-1.90 (m, 2H), 1.78-1.64 (m, 2H), 1.33 (d, J=6.80, 3H), MS(m/z): [M+H] calc'd for C.sub.20H.sub.20BrClFN.sub.3O, 454.0 and 452.1; found, 454.0 and 452.1. HPLC t.sub.R=5.09 min (HPLC method 1); purity=99.0%.
Example 14
5,6-dichloro-1-(1-(4-chloro-2-fluorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(88) ##STR00046##
(89) This compound was made according to the method of Example 1, using 4-chloro-2-fluorobenzaldehyde in step 5. The overall yield was 49%.
(90) Supporting data for the product of Example 14 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 9.09 (s, 1H), 7.39 (t, J=8.06, 1H), 7.31 (s, 1H), 7.18-7.13 (m, 2H), 7.10 (dd, J=9.56, 1.84, 1H), 4.32-4.20 (m, 1H), 3.62 (s, 2H), 3.05 (d, J=11.53, 2H), 2.46-2.31 (m, 2H), 2.23 (t, J=11.56, 2H), 1.80 (d, J=10.20, 2H), MS(m/z): [M+H] calc'd for C.sub.19H.sub.17Cl.sub.3FN.sub.3O, 428.0 and 430.0; found. 428.3 and 430.2. HPLC t.sub.R=3.95 min (HPLC method 1); purity=96.3%.
Example 15
1-(1-(4-bromobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one
(91) ##STR00047##
(92) This compound was made according to the method of Example 1, using 4-bromobenzaldehyde in step 5. The overall yield was 55%.
(93) Supporting data for the product of Example 15 includes: .sup.1H NMR (400 MHz, CDCl.sub.3) 8.68 (s, 1H), 7.47 (d, J=7.88, 2H), 7.32 (s, 1H), 7.29-7.22 (m, 2H), 7.15 (s, 1H), 4.35-4.23 (m, 1H), 3.52 (s, 2H), 3.02 (d, J=11.44, 2H), 2.44-2.29 (m, 2H), 2.15 (t, J=11.58, 2H), 1.78 (d, J=10.60, 2H), MS(m/z): [M+H] calc'd for C.sub.19H.sub.18BrCl.sub.2N.sub.3O, 454.00 and 456.00; found, 454.32 and 456.22. HPLC to =3.99 min (HPLC method 1); purity=95.9%.
Example 16
1-(1-(4-chlorobenzyl)piperidin-4-yl)-5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one
(94) ##STR00048##
(95) This compound was made according to the method of Example 1, using 4-chlorobenzaldehyde in step 5. The overall yield was 46%.
(96) Supporting data for the product of Example 16 includes: .sup.1H NMR (400 MHz, Methanol-d.sub.4) 7.60-7.52 (m, 4H), 7.49 (s, 1H), 7.19 (s, 1H), 4.53 (tt, J=12.3, 4.2 Hz, 1H), 4.39 (s, 2H), 3.65 (d, J=12.0 Hz, 2H), 3.30-3.20 (m, 2H), 2.73 (s, 5H), 2.08 (d, J=14.0 Hz, 2H); MS(m/z): [M+H] calc'd for C.sub.19H.sub.19Cl.sub.3N.sub.3O, 410.1; found, 410.1.
Example 17
1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-4-chloro-1H-benzo[d]imidazol-2(3H)-one
(97) ##STR00049##
(98) This compound was made according to the method of Example 12, using 2-fluoro-4-bromobenzaldehyde in step 5. The overall yield was 39%.
(99) Supporting data for the product of Example 17 includes: .sup.1H NMR (400 MHz, Methanol-d.sub.4) 7.65-7.55 (m, 3H), 7.20 (dd, J=5.9, 3.0 Hz, 1H), 7.13-7.05 (m, 2H), 4.54 (ddt, J=12.3, 8.2, 4.1 Hz, 1H), 4.45 (s, 2H), 3.71 (d, J=12.5 Hz, 2H), 3.36-3.30 (m, 2H), 2.80 (qd, J=13.5, 3.9 Hz, 2H), 2.71 (s, 3H), 2.10 (d, J=14.1 Hz, 2H); MS(m/z): [M+H] calc'd for C.sub.19H.sub.19BrClFN.sub.3O, 440.0 and 438.0; found, 440.0 and 438.0.
Example 18
1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-6-chloro-1H-benzo[d]imidazol-2(3H)-one
(100) ##STR00050##
(101) This compound was made according to the method of Example 6, using 2-fluoro-4-bromobenzaldehyde in the final step. The overall yield was 31%.
(102) Supporting data for the product of Example 18 includes: .sup.1H NMR (400 MHz, Methanol-d.sub.4) 7.64-7.54 (m, 3H). 7.36 (dd, J=1.9, 0.5 Hz. 1H), 7.11-6.99 (m. 2H), 4.55 (tt, J=12.3, 4.3 Hz, 1H), 4.45 (d, J=1.3 Hz, 2H), 3.70 (d. J=12.3 Hz, 2H), 3.36-3.30 (m, 2H). 2.83-2.72 (m, 5H), 2.09 (d, J=14.2 Hz, 2H); MS(m/z): [M+H] calc'd for C.sub.19H.sub.19BrClFN.sub.3O, 440.0 and 438.0; found, 440.0 and 438.0.
Example 19
5-chloro-1-(1-(1-(4-(difluoromethoxy)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(103) ##STR00051##
(104) This compound was made according to the method of Example 5, using 1-(4-(difluoromethoxy)phenyl)ethanone in the final step. The overall yield was 35%.
(105) Supporting data for the product of Example 19 includes: MS(m/z): [M+H] calc'd for C.sub.21H.sub.23ClF.sub.2N.sub.3O.sub.2, 422.1; found, 422.2.
Example 20
4-chloro-1-(1-(1-(4-(trifluoromethoxy)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(106) ##STR00052##
(107) This compound was made according to the method of Example 12, using 1-(4-(difluoromethoxy)phenyl)ethanone in the final step. The overall yield was 33%.
(108) Supporting data for the product of Example 20 includes: MS(m/z): [M+H] calc'd for C.sub.21H.sub.23ClF.sub.2N.sub.3O.sub.2, 422.1; found, 422.1.
Example 21
6-chloro-1-(1-(1-(4-chloro-2-fluorophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(109) ##STR00053##
(110) This compound was made according to the method of Example 6, using 1-(4-chloro-2-fluorophenyl)ethanone in the final step. The overall yield was 30%.
(111) Supporting data for the product of Example 21 includes: MS(m/z): [M+H] calc'd for C.sub.20H.sub.21Cl.sub.2FN.sub.3O, 408.1; found, 408.1.
Example 22
6-bromo-1-(1-(1-(4-(trifluoromethoxy)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(112) ##STR00054##
(113) This compound was made according to the method of Example 8, using 1-(4-(trifluoromethoxy)phenyl)ethanone in the final step. The overall yield was 33%.
(114) Supporting data for the product of Example 22 includes: MS(m/z): [M+H] calc'd for C.sub.21H.sub.22BrF.sub.3N.sub.3O.sub.2, 486.1 and 484.1; found 486.1 and 484.1.
Example 23
6-bromo-1-(1-(1-(4-chloro-2-fluorophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(115) ##STR00055##
(116) This compound was made according to the method of Example 8, using 1-(4-chloro-2-fluorophenyl)ethanone in the final step. The overall yield was 28%.
(117) Supporting data for the product of Example 23 includes: MS(m/z): [M+H] calc'd for C.sub.20H.sub.21BrClFN.sub.3O, 454.0 and 452.0; found 454.1 and 452.1.
Example 24
4,6-dichloro-1-(1-(1-(4-methoxyphenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(118) ##STR00056##
(119) This compound was made according to the method of Example 1, but using 1,5-dichloro-3-fluoro-2-nitrobenzene as the starting material in step 1, and using 1-(4-methoxyphenyl)ethanone in the final step while using procedure B, with titanium (IV) isopropoxide added prior to the addition of the reducing agent, which was in this case NaBH.sub.3CN. The overall yield was 21%.
(120) Supporting data for the product of Example 24 includes: [M+H] calc'd for C.sub.21H.sub.24Cl.sub.2N.sub.3O.sub.2, 420.1; found 420.1.
Example 25
5,6-dichloro-1-(1-(2-fluoro-4-methylbenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(121) ##STR00057##
(122) This compound was made according to the method of Example 1, using 2-fluoro-4-methylbenzaldehyde in step 5. The overall yield was 32%.
(123) Supporting data for the product of Example 25 includes: [M+H] calc'd for C.sub.20H.sub.21Cl.sub.2FN.sub.3O, 408.1; found 408.2. .sup.1H NMR of the mesylate salt (400 MHz, MeOD) 7.54-7.50 (m, 2H), 7.22-7.15 (m, 3H), 4.56 (tt, J=12.2, 4.0 Hz, 1H), 4.43 (s, 2H), 3.70 (d, J=12.8 Hz, 2H), 3.35-3.29 (m, 2H), 2.82-2.71 (m, 8H), 2.44 (s, 3H), 2.10 (d, J=14.4 Hz, 2H); HPLC t.sub.R=3.692 min (HPLC method 1); purity >90%.
(124) Compounds of the invention may also be prepared as described in the General Reaction Scheme 2 shown below:
(125) ##STR00058## ##STR00059##
(126) The following compounds were made according to the methods of General Scheme 2:
(127) TABLE-US-00002 TABLE 2 step 3 reaction identification example structure R groups conditions numbers 26
Example 26
4-chloro-1-(1-(2-chlorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(128) ##STR00062##
(129) Step 1. Follows step 1 of Example 1, except that the solvent was DMF, while 1-chloro-3-fluoro-2-nitrobenzene was used as the starting material. This provided tert-butyl 4-((3-chloro-2-nitrophenyl)amino)piperidine-1-carboxylate as the product. The yield was 93%.
(130) Step 2. Follows step 4 of Example 1, treatment with TFA:CH.sub.2Cl.sub.2, using the product of step 1 (this example), tert-butyl 4-((3-chloro-2-nitrophenyl)amino)piperidine-1-carboxylate, as the starting material and providing N-(3-chloro-2-nitrophenyl)piperidin-4-amine as the product. The yield of the crude material, taken to the next step without chromatographic purification, was 88%.
(131) Step 3. Follows step 5 of Example 1, the NaBH(OAc).sub.3-promoted reductive alkylation reaction, using the product of step 2 (this example), N-(3-chloro-2-nitrophenyl)piperidin-4-amine, and 2-chlorobenzaldehyde as the starting materials and giving N-(3-chloro-2-nitrophenyl)-1-(2-chlorobenzyl)piperidin-4-amine as the product, after purification by column chromatography using 15:85 hexane:ethyl acetate containing 0.1% Et.sub.3N as eluent. The yield was 91%.
(132) Step 4. The product of step 3, N-(3-chloro-2-nitrophenyl)-1-(2-chlorobenzyl)piperidin-4-amine (379 mg, 1 mmol), was dissolved in 3 mL of a 1:2:6 solvent mixture of water:THF:ethanol. Iron powder (450 mg, 8 mmol, 8 equiv.) was added in one portion. The solution was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (5 mL) and this solution was filtered through Celite and the pad was washed with ethanol (35 mL). The solution was concentrated under reduced pressure. Purification was achieved by flash column chromatography on silica gel using 2% to 10% gradient of hexane in ethyl acetate containing 0.1% Et.sub.3N as eluent. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as an oil. 231 mg of the product 3-chloro-N.sup.1-(1-(2-chlorobenzyl)piperidin-4-yl)benzene-1,2-diamine (66%).
(133) Step 5. A portion of the product of step 3, 3-chloro-N.sup.1-(1-(2-chlorobenzyl)piperidin-4-yl)benzene-1,2-diamine (118 mg, 0.34 mmol), was dissolved in dichloromethane (5 mL). Et.sub.3N (130 L, 94 mg, 0.93 mmol, 2.7 equiv.) was added, followed by triphosgene (45 mg, 0.15 mmol). The solution was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (5 mL).
(134) This solution was washed with cold 1M HCl (22 mL) and water (22 mL). The organic layer was dried using MgSO.sub.4 and the solvent was removed under reduced pressure. Purification was achieved by flash column chromatography on silica gel using a gradient of 0-20% methanol in dichloromethane as eluent, with each solvent containing 0.1% Et.sub.3N. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as a yellow oil. 102 mg of the product 4-chloro-1-(1-(2-chlorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one was obtained (81%).
(135) Supporting data for the product of Example 26 includes: .sup.1H NMR (400 MHz, MeOD) 7.71 (dd, J=7.40, 1.92, 1H), 7.62 (dd, J=8.00, 1.55, 1H), 7.57-7.47 (m, 2H), 7.22 (dd, J=7.02, 1.86, 1H), 7.11-7.03 (m, 2H), 4.65-4.55 (m, 3H), 3.73 (d, J=12.04, 2H), 3.43 (t, J=12.26, 2H), 2.81 (d, J=13.31, 2H), 2.09 (d, J=14.80, 2H), MS(m/z): [M+H] calc'd for C.sub.19H.sub.19Cl.sub.2N.sub.3O 376.1, 378.1, found 376.2, 378.1. HPLC t.sub.R=3.49 min (HPLC method 1); purity=99.9%.
Example 27
4-chloro-1-(1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(136) ##STR00063##
(137) Step 1 and 2: repeats steps 1 and 2 of Example 26.
(138) Step 3. Follows step 5 of Example 2, the procedure using Ti(Oi-Pr).sub.4 and NaBH(OAc).sub.3, with N-(3-chloro-2-nitrophenyl)piperidin-4-amine and 1-(4-chlorophenyl)ethanone as the starting materials and providing N-(3-chloro-2-nitrophenyl)-1-(1-(4-chlorophenyl)ethyl)piperidin-4-amine as the product. The yield was 87%.
(139) Steps 4 and 5. Follows steps 4 and 5 of Example 26, beginning with N-(3-chloro-2-nitrophenyl)-1-(1-(4-chlorophenyl)ethyl)piperidin-4-amine and providing 4-chloro-1-(1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one as the product. The yield was 52% for two steps.
(140) Supporting data for the product of Example 27 includes: .sup.1H NMR (400 MHz, MeOD) 7.61-7.50 (m, 4H), 7.21 (dd, J=7.08, 1.64, 1H), 7.11-7.00 (m, 2H), 4.57 (q, J=6.64, 1H), 4.52-4.41 (m, 1H), 3.88 (d, J=11.44, 1H), 3.52 (d, J=12.96, 1H), 3.20-2.98 (m, 2H), 2.93-2.7 (m, 2H), 2.16-1.96 (m, 2H), 1.81 (d, J=6.96, 3H). MS(m/z): [M+H] calc'd for C.sub.20H.sub.21Cl.sub.2N.sub.3O 390.1, 392.1, found 390.2, 392.1. HPLC t.sub.R=3.71 min (HPLC method 1); purity=99.9%.
(141) Anticipated procedural variations for Examples 26-27: The reagents used in these methods are fully suited for the indicated syntheses but an experimentalist is not limited to the described reagents and/or reaction conditions, as one of ordinary skill may recognize other suitable reagents and/or reaction conditions. Specific common variants are here specified: While tert-butyl 4-aminopiperidine-1-carboxylate was used as the starting material, other N.sup.1-protecting groups on the 4-aminopiperidine reactant can instead be used, with a corresponding adjustment in how step 2 (protecting group removal) is conducted. Bases and solvents other than the indicated EtN(i-Pr).sub.2 in DMF method are suitable for use in step 1. Other reaction conditions and/or reducing agents may be used in step 3 to form the indicated products. Reducing conditions other than the indicated combination of iron powder in acetic acid can be used for nitro group reduction in step 4. Reagents other than triphosgene can be used in step 5 to form the benzimidazolone ring, including a phosgene solution or carbonyl diimidazole. Purification methods other than flash chromatography may alternatively be used (e.g., preparative HPLC, recrystallization, etc.).
(142) Compounds of the invention may also be prepared as described in the General Reaction Scheme 3 shown below:
(143) ##STR00064##
(144) The following compounds were made according to the method of General Scheme 3:
(145) TABLE-US-00003 TABLE 3 step 6 reaction identification example structure R groups conditions numbers 28
Example 28
1-(1-(2-chlorobenzyl)piperidin-4-yl)-3-(cyclopropylmethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one
(146) ##STR00067##
(147) Steps 1-5. The compound 1-(1-(2-chlorobenzyl)piperidin-4-yl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one was made following the methods of General Scheme 2 for steps 1-5, using 1-fluoro-4-methyl-2-nitrobenzene in step 1 and 4-chlorobenzaldehyde in step 3. The overall yield for the 5 step route was 41%.
(148) Step 6. To the product of step 5 (18.0 mg, 0.05 mmol) in DMF (2 mL) was added 50% NaH in mineral oil (20 mg, 10 mg NaH, 0.42 mmol, 8 equiv.) and (bromomethyl)cyclopropane (24.3 mg, 0.18 mmol, 3.6 equiv.). The solution was stirred at room temperature for 4 hours. Water (5 mL) was added, followed by ethyl acetate (5 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (25 mL). The combined organic layers were dried using MgSO.sub.4 and the solvent was removed under reduced pressure. Purification was achieved by flash column chromatography on silica gel using a gradient of 0-20% methanol in dichloromethane as eluent, with each solvent containing 0.1% Et.sub.3N. Fractions containing the desired product were pooled and concentrated under reduced pressure to give the product as a light yellow oil. This oil was dissolved in a minimal amount of water-acetonitrile (1:1). Trifluoroacetic acid (15 L) was added. The solution was frozen and subjected to lyophilization overnight, giving the product as a tan solid, in the form of a trifluoroacetic acid salt. 13.2 mg of the product 1-(1-(2-chlorobenzyl)piperidin-4-yl)-3-(cyclopropylmethyl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one (trifluoroacetic acid salt) was obtained (64%).
(149) Supporting data for the product of Example 28 includes: MS(m/z): [M+H] calc'd for C.sub.24H.sub.28ClN.sub.3O 410.2, found 410.2. HPLC t.sub.R=4.09 min (HPLC method 1); purity=99.9%.
Example 29
5-chloro-3-(cyclopropylmethyl)-1-(1-(1-(p-tolyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
(150) ##STR00068##
(151) This compound was made following the methods of Example 28. General Scheme 2 was used for steps 1-5, using 1-fluoro-4-chloro-2-nitrobenzene in step 1 and 4-methylacetophenone in the reductive amination step, with titanium isopropoxide and NaBH.sub.3CN used. The overall yield for the 5 step route was 27%.
(152) Supporting data for the product of Example 29 includes: MS(m/z): [M+H] calc'd for C.sub.25H.sub.31ClN.sub.3O 424.2, found 424.2.
(153) Anticipated procedural variations for Examples 29-30: The reagents used in these methods are fully suited for the indicated synthesis but an experimentalist is not limited to the described reagents and/or reaction conditions, as one of ordinary skill may recognize other suitable reagents and/or reaction conditions. Strong bases other than sodium hydride may be used in step 6. Examples of such suitable bases include LiN(i-Pr).sub.2, LiN(SiMe.sub.3).sub.2, and KOt-Bu. The choice of conditions may vary depending upon the properties of both the benzimidazolone substrate and the electrophile R.sup.8X. Purification methods other than flash chromatography may alternatively be used (e.g., preparative HPLC, recrystallization, etc.).
(154) Biological Assessment Methods
(155) In Vitro Pharmacology Assays:
(156) G protein signaling assays: A standard [.sup.35S]GTPS binding assay in membranes prepared from CHO cells expressing the human MOR was performed in a concentration response manner. All compounds were run in parallel with DAMGO and morphine.
(157) cAMP inhibition assays: The CisBio cAMP cell based assay kit that uses HTRF technology was utilized to assess MOR-mediated inhibition of cAMP. Assays were performed according to manufacturer's instructions, in the presence of 20 M forskolin and 25 M PDE-IV. All compounds were run in parallel with DAMGO and morphine.
(158) arrestin2 recruitment assays: The commercial enzyme fragment complementation assay PathHunter from DiscoveRx, Fremont Calif., was used to assess recruitment of arrestin2 to the human MOR in U2OS cells. Assays were performed according to manufacturer's instructions. All compounds were run in parallel with DAMGO and morphine.
(159) MOR phosphorylation assays: HAmMOR HEK cells were treated with drug for 10 minutes and then the receptor was immunoprecipitated using anti-HA agarose beads. MOR phosphorylation at serine375 was determined by immunoblotting with the Cell Signaling antibody.
(160) Bias Analysis:
(161) Bias calculations were made by applying the dose response data, obtained from experiments run in parallel with the reference ligand, to the operational model as defined by Black and Leff (25) as modified for Prism software, GraphPad, (La Jolla, Calif.), and applied as presented by Kenakin and Christopoulos (27). The relative activity of an agonist in each assay is simultaneously compared to the relative activity of the reference compound, in this case DAMGO, and following mathematically transformation, a normalization of the potential of the test compound to produce a response is garnered in the form of the transduction coefficient or the Log(/K.sub.A) or Log R as represented in the program. Comparison of the performance of the compound across two assays can be made to generate a Log(/K.sub.A) or the Bias Factor, the latter term is used in this report. A higher Bias Factor indicates a greater performance of a test compound compared to DAMGO in one assay over another (i.e., G protein/arrestin2).
(162) Antinociception:
(163) The mouse hot plate test and warm water tail immersion test have been extensively described and have been used to assess antinociceptive drug properties; all opioid analgesics that are potent in humans induce antinociception in these mouse pain assays. The mouse hot plate (Columbus Instruments, Columbus, Ohio) was set to a steady temperature of 52 C. Baseline response latencies were established prior to drug treatment (approximately 6 seconds). A response was considered any motion indicating an attempt to remove a paw from the hot surface. A similar approach was taken in the mouse warm water tail immersion (tail flick) test. Water temperature was maintained at 49 C. producing a baseline latency for response (flicking or removing the tail from the water) of approximately 3 seconds. For both tests, drugs were administered systemically (in many cases, tested both i.p. and s.c.) and response latencies were measured every 30 minutes for up to 6 hours. Antinociception was observed when the response latencies were significantly greater than baseline measures (=0.05, t-test or ANOVA). In each type of experiment a time cutoff was imposed to prevent injury, in accord with regulations for animal care (approved IACUC protocols) in such experiments.
Biological Activity of Representative Compounds of the Invention
Example 30
(164) The following table summarizes the biological activity of specific claimed compounds that were described in the Examples.
(165) TABLE-US-00004 TABLE 4 G protein coupling bias G protein bias (GTPS factor coupling factor anti- assay) G/arr2 (cAMP assay) G/arr2 nociceptive in vivo ID EC.sub.50 E.sub.max /KA EC.sub.50 E.sub.max /KA activity in models # numbers (nM) (%) GTPS (nM) (%) cAMP vivo (mice) assessed 1 S186 67 43 >10 89 105 >10 yes hot plate & SR-14249 tail flick 2 S186.002 16 83 6.7 7 99 1.6 not tested SR-14963 3 S86.025 43 71 >10 30 103 8.7 yes hot plate & SR-12968 tail flick, respiratory suppression 4 S86.033 223 65 9.6 319 110 2.3 yes hot plate & SR-14152 tail flick, respiratory suppression, whole gut transit, locomotor activity 5 S86.014 291 28 5.8 622 81 1.3 not tested SR-11503 6 S112.061 2.0 94 >10 1 101 4.3 not tested SR-14167 7 S86.023 33 83 8.8 25 106 3.4 yes hot plate & SR-11794 tail flick, whole gut transit 8 S112.082 2.5 95 >10 1 105 >10 not tested SR-14979 9 S112.064 45 88 6.2 35 109 2.6 not tested SR-14220 10 S86.037 279 73 5.3 258 98 1.5 not tested SR-14219 11 S86.013 13 91 4.4 10 102 1.6 yes hot plate & SR-11502 tail flick 12 S112.062 2.3 93 4.2 1 105 2.2 not tested SR-14206 13 S112.049 19 91 3.4 4 98 3.1 yes hot plate & SR-13406 tail flick 14 S186.004 116 62 >10 112 104 8.1 yes hot plate & SR-15098 tail flick, respiratory suppression, whole gut transit 15 S186.005 144 73 >10 92 101 >10 yes hot plate & SR-15099 tail flick, respiratory suppression, whole gut transit, locomotor activity 16 S186.006 122 68 >10 83 106 >10 yes hot plate & SR-17018 tail flick 17 S112.084 58 93 3.1 not tested not tested SR-16299 18 S112.086 140 92 7.4 119 103 2.0 not tested SR-16301 19 S86.026 15 89 4.0 not tested not tested SR-13403 20 S112.034 30 98 3.1 not tested not tested SR-12032 21 S112.041 14 91 3.6 3 96 4.1 yes hot plate & SR-12038 tail flick 22 S112.076 39 100 3.3 not tested not tested SR-14973 23 S112.077 21 102 3.4 not tested not tested SR-14974 24 S184 0.4 94 4.6 0.4 107 1.5 not tested SR-12306 25 S186.011 66 77 3.0 32 104 1.9 not tested SR-18586 26 S112.001 36 94 4.0 55 116 1.1 not tested SR-11099 27 S112.027 3.1 89 5.0 3 108 1.6 not tested SR-11964 28 S112.006 558 88 4.4 253 103 2.7 not tested SR-11427 29 S86.020 12 83 3.3 not tested not tested SR-11712
In Vivo Pharmacology Studies in Mice, Demonstrating Antinociceptive Efficacy and Attenuated Side Effects
Example 31: Analgesic Potencies, Expressed by Area Under the Curve Analysis, for Selected Compounds Compared to Morphine Sulfate in the Hot Plate (52 C.) and Warm Water (49 C.) Tail Immersion (Tail Flick) Tests
(166) The identification numbers shown correspond to those in column 2 of Table 4 and can readily be cross-referenced to the corresponding synthesis Example.
(167) All results were analyzed by subtracting baselines and establishing area under the curve analysis over a 6 hour time frame. A 20 second max was applied to the hot plate and a 30 second max was applied to the tail flick assay to prevent injury. All doses were prepared as base weight of TSRI compounds and the salt weight of morphine sulfate. Results are shown in
Example 32: Antinociception and Constipation Induced by Compound S086.025 (the Product of Example 3), Following Acute and Following Chronic Administration
(168) S086.025 (G/arr2 bias factor >10, using the [.sup.35S]GTPS binding assay) induces robust antinociception that is more pronounced and that also lasts longer than morphine sulfate in both the hot plate (52 C.) and warm water (49 C.) tail immersion (tail flick) tests. Area under the curve analysis for this compound is shown in Example 31 (orange filled circles). In a separate cohort of animals, fecal boli production was evaluated after a 3 mg/kg s.c. dose of S086.025; this was compared to a near equianalgesic dose of morphine sulfate (6 mg/kg, s.c. in tail flick tests; analgesic data is not shown for s.c. dosing, however it was very similar to that seen following i.p. dosing). Following acute administration, both morphine and S086.025 induced constipation. However, following chronic administration of S086.025, (3 mg/kg every 12 hours for 3 days, then 6 mg/kg every 12 hours for 2 days), mice were again tested for constipation (post chronic, 3 mg/kg, s.c.). The animals treated chronically with S086.025 ceased responding to the drug relative to control, suggesting that constipation no longer occurs. In the same cohort of animals, baseline responses in the hot plate test were taken after the 6 hour boli collection and then a second challenge dose of S086.025 (6 mg/kg, s.c.) was given. Antinociceptive responses taken at one hour were not different between the acute treatment group and the group that had received chronic drug treatment. These findings suggest that the mice become rapidly desensitized to the acute constipating effects of S086.025, but they do not become desensitized to the antinociceptive effects, suggesting that constipation and analgesic efficacy can be separated by using this biased mu opioid agonist. The predominant cause of persistent constipation is due to non-tolerizing opioid agonism in the colon; while the upper GI effects do wane overtime. The Bohn lab has proposed the hypothesis that arrestins mediate opioid-induced constipation by activating MOR in the colon per se (17). Results are shown in
Example 33: Separation of Analgesic Efficacy and Respiratory and Cardiovascular Side Effects
(169) Antinociceptive, respiratory and cardiovascular responses to S086.033 (G/arr2 bias factor >10) analyzed per dose over time in C57BL/6 male mice. Antinociceptive data were obtained in a 52 C. hotplate (20 sec cutoff imposed) and a 49 C. warm water tail flick test (30 sec cutoff imposed). For respiratory measures, shaved male C57BL/6 mice were habituated to conical tube restraints for 1 day prior to testing and on the test day for 1 hour and testing was performed with a MouseOx pulse oximeter. Results are shown in
(170) Area under the curve (AUC) analysis was performed following subtraction of baseline responses. The antinociceptive response period was 6 hours, wherein testing occurred as shown in Example 31. For respiratory and cardiology measures, mice were treated as described in Example 33.1. All parameters were simultaneously recorded. Area under the curve analysis was performed by subtracting baseline measures obtained for the first 30 minutes of data for each dose during a 1 hour test period after compound injection. At all doses tested, S086.033 produced an equal antinociceptive response equal to or exceeding that of morphine while producing results in several measured parameters (% O.sub.2 saturation, respiratory frequency, heart rate) that indicate diminished or even absent side effects, in comparison to morphine. At or even above the equianalgesic dose (relative to morphine) and at or even above the maximal effective dose of ca.12 mg/kg, i.p., effects of S086.033 did not differ from that of vehicle in these respiratory or cardiovascular measures. These findings demonstrate that biased MOR agonists may be useful in producing antinociception with improved safety margins.
Example 34: Differential Effects on MOR Phosphorylation
(171) Agonist-induced MOR phosphorylation at serine 375 was determined by immunoprecipitating the HA-MOR. DAMGO and morphine both induce phosphorylation at 1 M concentrations. S086.033 (G/arr bias factor=9.6) and S186-005 (G/arr bias factor >10) only induce slight phosphorylation at 10 M.
Example 35: Selected Data Regarding Modes of Dosing In Vivo and Pharmacokinetic Properties
(172) Compounds of the invention to be used for the relief of pain (in its many forms) may be administered by many different modes that are common in the field, such as (but not limited to) oral dosing, subcutaneous dosing, i.v. dosing, and transdermal delivery. The suitability of selected compounds of the invention for delivery to mice by various modes, including intraperitoneal (i.p) dosing is illustrated in this Example. The suitability of multiple modes of compound delivery in rodents serves to support the feasibility of various dosing strategies common in the field in higher mammals, including man.
(173) The top two panels below shows plasma and brain levels of S186.005 at various time points following i.p. dosing at 6 mg/kg. The test compound is readily detected at multiple time points at which, in an analogous experiment, morphine administered at the same dose is not detectable.
(174) Below the plasma and brain level data is shown many standard pharmacokinetic parameters measured for morphine and for the test compound S186.005, delivered intraveneously (i.v.) at 1 mg/kg or orally (p.o.) at 3 mg/kg. Relative to morphine, by either route of administration 5186.005 has a longer plasma half-life, reaches a higher maximum plasma concentration, has higher exposure by AUC calculations, and is cleared less rapidly.
(175) As shown above, S186.005 has significant oral bioavailability in mice (51%), as do other selected compounds of the invention (data not shown). Thus the data such as shown earlier in Example 31, analgesic potencies, expressed by area under the curve analysis, for selected compounds compared to morphine sulfate in the hot plate (52 C.) and warm water (49 C.) tail immersion (tail flick) tests following i.p. dosing may, for certain compounds of the invention, be similarly generated following p.o. dosing. Shown in
Aspects of Compounds of the Invention as Related to Prior Art
(176) The substituents R.sup.1-R.sup.7 in general structure 1 (
(177) TABLE-US-00005 TABLE 5 Bias Factor ex- G/arr2 am- GTPS /KA ple structure EC.sub.50 GTPS 4
Definitions and Abbreviations
(178) The term GPCR as used herein refers to a G protein-coupled receptor, which is one member of a diverse family of glycoproteins which share certain structural features. These include the existence of seven hydrophobic stretches of about 20-25 amino acids each surrounded by eight hydrophilic regions of variable length. Each of the seven hydrophobic regions is thought to form a transmembrane alpha helix and the intervening hydrophilic regions form alternately intracellularly-exposed and extracellularly-exposed loops.
(179) The term MOR as used herein refers to the GPCR commonly named the mu opioid receptor.
(180) The term agonist as used herein refers to a compound that activates a GPCR, causing structural changes within the receptor complex in the absence of other receptor ligand, changes that result in the propagation of receptor signaling pathways.
(181) The term partial agonist as used herein refers to a compound that binds to a receptor site but does not produce the maximal effect regardless of its concentration.
(182) The term ligand as used herein refers to a compound that binds at the receptor site.
(183) The term bias as used here refers to the preference of a ligand to activate one signaling pathway over another as determined by dose response comparison of the ligand to a reference ligand that is used to define the potential of the assay system.
(184) The term reference agonist as used here defines an agonist that produces a maximal response in the cell based assay to which all other ligands are compared.
(185) The term bias factor is a mathematically derived value obtained by nonlinear regression analysis of the dose response curves fit relative to the full potential curve obtained by the reference agonist's performance between two assays. This analysis produces the relative affinity of the test compound and the relatively efficiency of coupling compared to the reference compound's performance in the system. The difference between the performance of the test compound in assay 1, normalized to the reference compound, and its performance in assay 2, normalized to the reference compound, produces the bias factor. The bias factors may diverge with different analyses. A truly biased agonist will have a bias factor that is significantly different than 1.
(186) The term heteroatom as used herein refers to an atom of any element other than carbon or hydrogen. Common heteroatoms include nitrogen, oxygen, phosphorus, sulfur and selenium.
(187) The abbreviation CNS as used herein refers to the central nervous system of an organism.
(188) The term EC.sub.50 as used herein refers to the dose of a test compound which produces 50% of its maximum response or effect in an assay.
(189) The term ED.sub.50 as used herein refers to the dose of a test compound which produces 50% of its maximum response or effect in an animal experiment.
(190) The term E.sub.max as used herein refers to the degree of the effect of a test compound in an assay (percent activation, as an example) relative to the maximum response or effect in the assay resulting from the use of a reference compound.
(191) The term LD.sub.50 as used herein refers to the dose of a test compound which is lethal in 50% of test subjects in an animal experiment.
(192) The term structure-activity relationship or SAR as used herein refers to the way in which altering the molecular structure of test compounds alters their interaction with a receptor, enzyme, etc.
(193) The term electron-withdrawing group as used herein is recognized in the art, and denotes the tendency of a substituent to attract valence electrons from neighboring atoms, i.e., the substituent is electronegative with respect to neighboring atoms. A quantification of the level of electron-withdrawing capability is given by the Hammett sigma (a) constant.
(194) The term alkyl as used herein throughout the specification, examples, and claims refers to a hydrocarbon group, and includes branched chain variations.
(195) The term cycloalkyl as used herein throughout the specification, examples, and claims refers to a cyclic hydrocarbon group, and may include alkyl substituents on the cyclic hydrocarbon group.
(196) The term substituted alkyl as used herein refers to alkyl moieties having substituents replacing a hydrogen atom on one or more carbon atoms of the hydrocarbon backbone. Such substituents can include, for example, a halogen, a halogenated alkyl (e.g., CF.sub.3), a hydroxyl, a carbonyl, an amino, an amido, an amidine, an imine, an alkoxy, a halogenated alkoxy (e.g., OCF3, OCHF2, etc.) a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic group. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
(197) The term aryl as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as aryl heterocycles or heteroaromatics. The aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, CF3, CN, or the like. The term aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are fused rings) wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls. The terms ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho, meta-dimethylbenzene are synonymous.
(198) The term aralkyl as used herein refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group). Examples include CH.sub.2Ph, CH.sub.2CH.sub.2Ph, CH.sub.2CH.sub.2-indole, and the like. The aromatic ring can be substituted at one or more ring positions with such substituents, as described above.
(199) The terms alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
(200) Unless the number of carbons is otherwise specified. lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, lower alkenyl and lower alkynyl have similar chain lengths.
(201) The terms heterocyclyl or heterocyclic group as used herein refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings that include one to four heteroatoms. Heterocycles can also be polycycles. Heterocyclyl groups include, for example, azetidine, azepine, thiophene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, CF3, CN, or the like.
(202) The terms polycyclyl or polycyclic group refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are fused rings. Rings that are joined through non-adjacent atoms are termed bridged rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, CF3, CN, or the like.
(203) The term carbocycle, as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
(204) As used herein, the term halogen designates F, Cl, Br or I.
(205) As used herein, the term hydroxyl means OH.
(206) As used herein, the term sulfonyl means SO.sub.2.
(207) The terms amine and amino as used herein are recognized in the art and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formulas NH2, NHR, NRR, where R and R are alkyl, cycloalkyl, aryl, or heterocyclyl groups, as example.
(208) The terms alkoxyl or alkoxy as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
(209) The term ether as used herein refers to two hydrocarbons groups covalently linked by an oxygen atom.
(210) Various abbreviations used herein include Me, Et, Ph, Tf, Nf, Ts, Ms and represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, para-toluenesulfonyl and methanesulfonyl groups, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations. The abbreviations contained in said list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.
(211) The term sulfonamido is art recognized and includes a moiety that can be represented by the general formula SO.sub.2N(R)(R) wherein where R, and R are alkyl, cycloalkyl, aryl, or heterocyclyl groups, as examples.
(212) The term sulfonyl, as used herein, refers to a moiety that can be represented by the general formula SO.sub.2R wherein where R is an alkyl, cycloalkyl, aryl, or heterocyclyl group, as examples.
(213) Various substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.
(214) As used herein, the definition of each expression, e.g., alkyl, m, n, etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
(215) It will be understood that substitution or substituted with includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
(216) The phrase protecting group as used herein means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include carbamates of amines, esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).
(217) Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
(218) Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
(219) If a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, it may be isolated using chiral chromatography methods, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
(220) The term Example as used herein indicates the procedures followed for the preparation of a claimed compound, In general, the compounds of the present invention may be prepared by the methods illustrated in the general reaction schemes as, for example, described in the examples, or by modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures not mentioned here.
(221) It is understood that certain claimed molecules may stably exist in with isotopic variants among specific substituents, such as deuterium or tritium in the place of hydrogen. Such isotopic variants also fall within the scope of the invention.
(222) The term antinociception is defined is the blockade of the perception of a nociceptive stimulus wherein nociceptive is defined as somatic or visceral pain processed by a normal, unaltered nervous system (4).
(223) The term G protein signaling bias refers to a calculated bias factor comparing the performance of the test compound against the performance of a reference compound in a arrestin2 recruitment assay and a G protein coupling assay, normalized to reference standard. This is not implying that other arrestin pathways, such as that of receptor post-translational modifications or arrestin1 recruitment, are not differentially affected. Furthermore, this does not imply the recruitment of any particular heterotrimeric G protein subunits.
(224) In the Examples, certain abbreviations are be used for specific chemical reagents or solvents. These are defined as follows:
(225) DMSO=dimethyl sulfoxide, or Me.sub.2SO; THF=tetrahydrofuran; TFA=trifluoroacetic acid; DMF=N,N-dimethylformamide; triphosgene=Cl.sub.3COCOOCCl.sub.3; Ac=acetyl=(CH.sub.3CO); HPLC=high performance liquid chromatography; LCMS=an instrument consisting of an HPLC instrument linked to a mass spectrometer.
(226) It is understood that certain groups such as amines, carboxylates, sulfonates, etc. can bear a net overall charge. When such a group or groups are present in a claimed compound, pharmaceutically acceptable salt forms of the structure are implicitly encompassed in the claims as well. For example, a claim for a compound with one or more amino groups present in the structure also implicitly claims all pharmaceutically acceptable salt forms, such as hydrochloride, methanesulfonyl, formate, oxalate, tartrate salts, and the like.
(227) It is understood that certain claimed compounds may stably exist as hydrates or solvates. Such differing forms are also implicitly encompassed in the claims. Hydrates refer to molecules of water present in the crystal lattice. Solvates refer to molecules of a relatively benign solvent, such as ethanol, present in the crystal lattice.
(228) It is understood that certain claimed compounds in any form, including as a salt, hydrate, or solvate, may stably exist in multiple solid crystalline and/or amorphous forms. Such forms may confer different physical properties (e.g., rate of dissolution, stability, hydroscopicity). Such differing solid forms are also implicitly encompassed in the claims.
DOCUMENTS CITED
(229) 1. Pastemak G W, Pan Y X. 2013. Mu opioids and their receptors: evolution of a concept. Pharmacological reviews. 65(4):1257-317. PMCID: 3799236. 2. Pastemak G W. 2014. Opioids and their receptors: Are we there yet?Neuropharmacology. 76 Pt B:198-203. 3. Cox B M. 2013. Recent developments in the study of opioid receptors. Molecular pharmacology. 83(4):723-8. 4. Mogil J S. 2009. Animal models of pain: progress and challenges. Nature reviews Neuroscience. 10(4):283-94. 5. Manglik A, Kruse A C, Kobilka T S, Thian F S, Mathiesen J M, Sunahara R K, Pardo L, Weis W I, Kobilka B K, Granier S. 2012. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature. 485(7398):321-6. PMCID: 3523197. 6. Williams J T, Ingram S L, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans C J, Christie M J. 2013. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacological reviews. 65(1):223-54. PMCID: 3565916. 7. Urban J D, Clarke W P, von Zastrow M, Nichols D E, Kobilka B, Weinstein H, Javitch J A, Roth B L, Christopoulos A, Sexton P M, Miller K J, Spedding M, Mailman R B. 2007. Functional selectivity and classical concepts of quantitative pharmacology. The Journal of pharmacology and experimental therapeutics. 320(1):1-13. 8. Kenakin T. 2007. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends in pharmacological sciences. 28(8):407-15. 9. Violin J D, Lefkowitz R J. 2007. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends in pharmacological sciences. 28(8):416-22. 10. Bohn L M. Selectivity for G Protein or Arrestin-Meidated Signaling. In: Neve K, editor. Functional Selectivity of G Protein-Coupled Receptor Ligands: New Opportunities for Drug Discovery. 1st ed: Humana Press; 2009. p. 71-85. 11. Raehal K M, Schmid C L, Groer C E, Bohn L M. 2011. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacological reviews. 63(4):1001-19. PMCID: 3186080. 12. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villen J, Haas W. Kovacs J J, Shukla A K, Hara M R, Hemandez M, Lachmann A, Zhao S, Lin Y, Cheng Y, Mizuno K, Ma'ayan A, Gygi S P, Lefkowitz R J. 2010. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proceedings of the National Academy of Sciences of the United States of America. 107(34):15299-304. PMCID: 2930550. 13. Raehal K M, Bohn L M. 2014. beta-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handbook of experimental pharmacology. 219:427-43. 14. Bohn L M, Gainetdinov R R, Lin F T, Lefkowitz R J, Caron M G. 2000. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 408(6813):720-3. 15. Bohn L M, Lefkowitz R J, Caron M G. 2002. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 22(23):10494-500. 16. Bohn L M, Lefkowitz R J, Gainetdinov R R, Peppel K, Caron M G, Lin F T. 1999. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 286(5449):2495-8. 17. Bohn L M, Raehal K M. 2006. Opioid receptor signaling: relevance for gastrointestinal therapy. Current opinion in pharmacology. 6(6):559-63. 18. Raehal K M, Walker J K, Bohn L M. 2005. Morphine side effects in beta-arrestin 2 knockout mice. The Journal of pharmacology and experimental therapeutics. 314(3):1 195-201. 19. Raehal K M, Bohn L M. 2011. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 60(1):58-65. PMCID: 2981657 20. Bohn L M, Caron, M. G., Lin, F, Lefkowitz, R J. 2003 (filed December 1999). U.S. Pat. No. 6,528,271Inhibition of .beta.arrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia. 21. Bohn L M, McDonald P H. 2010. Seeking Ligand Bias: Assessing GPCR Coupling to Beta-Arrestins for Drug Discovery. Drug discovery today Technologies. 7(1):e37-e42. PMCID: 3014586. 22. DeWire S M, Yamashita D S, Rominger D H, Liu G, Cowan C L, Graczyk T M, Chen X T, Pitis P M, Gotchev D, Yuan C, Koblish M, Lark M W, Violin J D. 2013. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. The Journal of pharmacology and experimental therapeutics. 344(3):708-17. 23. Soergel D G, Subach R A, Bumham N, Lark M W, James I E, Sadler B M, Skobieranda F, Violin J D, Webster L R. 2014. Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain. 155(9):1829-35. 24. Soergel D G, Subach R A, Sadler B, Connell J, Marion A S, Cowan C L, Violin J D, Lark M W. 2014. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. Journal of clinical pharmacology. 54(3):351-7. 25. Black J W, Leff P, Shankley N P, Wood J. 1985. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. British journal of pharmacology. 84(2):561-71. PMCID: 1987296. 26. Groer C E, Schmid C L, Jaeger A M, Bohn L M. 2011. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. The Journal of biological chemistry. 286(36):31731-41. PMCID: 3173119. 27. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A. Novick S. 2012. A simple method for quantifying functional selectivity and agonist bias. ACS chemical neuroscience. 3(3):193-203. PMCID: 3369801. 28. Schmid C L, Streicher J M, Groer C E, Munro T A, Zhou L, Bohn L M. 2013. Functional selectivity of 6-guanidinonaltrindole (6-GNTI) at kappa-opioid receptors in striatal neurons. The Journal of biological chemistry. 288(31):22387-98. PMCID: 3829329. 29. Zhou L, Lovell K M, Frankowski K J, Slauson S R, Phillips A M, Streicher J M, Stahl E, Schmid C L, Hodder P, Madoux F, Cameron M D, Prisinzano T E, Aube J, Bohn L M. 2013. Development of functionally selective, small molecule agonists at kappa opioid receptors. The Journal of biological chemistry. 288(51):36703-16. PMCID: 3868780. 30. Janssen P A. 1967. Derivatives of benzimidazolinyl piperidine, U.S. Pat. No. 3,318,900. 31. Teranishi Mea. 1983. Novel piperidine derivatives and pharmaceutical compositions containing same, EP0092391. 32. Den Hartog JAGea. 2005. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors, WO 2005/028466. 33. Patel V, Bhatt N, Bhatt P, Joshi H D. 2014. Synthesis and pharmacological evaluation of novel 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one derivatives as potential antimicrobial agents. Med Chem Res. 23(4):2133-9. 34. Lipinski C A. 2004. Lead- and drug-like compounds: the rule-of-five revolution. Drug discovery today Technologies. 1 (4):337-41. 35. Pajouhesh H. Lenz G R. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRx: the Journal of the American Society for Experimental NeuroTherapeutics. 2(4):541-53. PMCID: 1201314.
(230) All patents and publications referred to herein are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference in its entirety.